A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Recruiting
Phase 1
Interventional Study
AML (Acute Myeloid Leukemia)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Charm Therapeutics · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The main questions the study aims to answer are:
* What is an appropriate dose of CHM-029?
* What side effects may occur with CHM-029?
* How does the body process CHM-029?
Researchers will evaluate increas…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18 years old and above
* Relapsed or refractory (R/R) acute myeloid leukemia (AML) and has had treatment with any available standard therapies
* Positive for NPM1 mutation, or KMT2A or NUP98 rearrangements
Exclusion Criteria:
* White blood cell (WBC) count higher than 25,000…
Contacts